Quarterly report pursuant to Section 13 or 15(d)

Financial instruments (Details)

v3.5.0.2
Financial instruments (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2016
USD ($)
Feb. 29, 2016
USD ($)
$ / shares
shares
Mar. 31, 2016
USD ($)
$ / shares
shares
Sep. 30, 2016
USD ($)
item
shares
Sep. 30, 2016
CAD / shares
Sep. 30, 2016
USD ($)
Financial Instruments            
Cash, insured amount           $ 600,000
Accounts Payable, Trade, Current           2,400,000
Sales agreement maximum sales proceeds of stock issuance and sales       $ 10,000,000    
Common shares issued for cash, net $883 of issue costs $ 13,000   $ 164,979 5,686,000    
Stock issuance costs       $ 883,000    
Common shares issued for cash, net of issue costs (in shares) | shares     108,000      
Share Price | (per share)   $ 0.50 $ 0.65   CAD 0.64  
Sensitivity Analysis Of Fair Value Of Interests Continued To Be Held By Transferor Servicing Assets Or Liabilities Change In Basis Points | item       100    
Credit Concentration Risk            
Financial Instruments            
Cash, uninsured amount           $ 9,900,000
Minimum | Credit Availability Concentration Risk            
Financial Instruments            
Debt Instrument, Term       0 years    
Maximum | Credit Availability Concentration Risk            
Financial Instruments            
Debt Instrument, Term       5 years    
Capital Stock            
Financial Instruments            
Common shares issued for cash, net $883 of issue costs   $ 5,700,000   $ 5,686,000    
Stock issuance costs   $ 766,000        
Common shares issued for cash, net of issue costs (in shares) | shares   12,900,000   13,085,979